目的：观察临床分离的产超广谱β-内酰胺酶大肠埃希菌（ESBL-EC）对常用抗菌药物的耐药性变迁情况及药物治疗效果。方法：监测ESBL-EC的耐药趋势并分析临床药物的治疗结果。结果：ESBL-EC对头孢他啶、左氧氟沙星、头孢哌酮舒巴坦、阿米卡星、头孢西丁、哌拉西林他唑巴坦、亚胺培南的平均耐药率分别为64.4%、62.5%、8.7%、9.6%、1.9%、0%、0%；对头孢曲松几乎全部耐药。亚胺培南西司他汀、头孢西丁、头孢哌酮舒巴坦、哌拉西林他唑巴坦对ESBL-EC感染临床治疗效果较好，依替米星治疗效果不佳。结论：临床及时监控ESBL-EC的发生率及其耐药趋势以指导临床用药至关重要。
Abstract
Objective: To observe the changes of drug resistance of extended spectrum β-lactamase-producing escherichia coli (ESBL-EC) clinically isolated to common antibiotics and the clinical treatment effect. Methods: The drug resistance trend of ESBL-EC was monitored and the clinical treatment effect was analyzed. Results: The average resistance rates of ESBL-EC to ceftazidime, levofloxacin, cefoperazone sulbactam, amikacin, cefoxitin, piperacillin tazobactam and imipenem were 64.4%, 62.5%, 8.7%, 9.6%, 1.9%, 0% and 0% respectively. The resistance rate to ceftriaxone was almost 100%. Imipenem cilastatin, cefoxitin, cefoperazone sulbactam and piperacillin tazobactam were effective in the treatment of ESBL-EC infection, and the clinical treatment effect of etimicin was not good. Conclusion: The incidence of ESBL-EC and its drug resistance trend should be clinically monitored in time so as to guide the clinical medication of drugs.
关键词
产超广谱β-内酰胺酶大肠埃希菌;药物敏感性试验;细菌耐药监测;药物治疗
{{custom_keyword}} /
Key words
extended spectrum β-lactamase-producing escherichia coli;drug sensitivity test;bacterial resistance monitoring;medication
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 周华,李光辉,陈佰,等. 中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J]. 中华医学杂志,2014,94(24):1847-1856.
[2] Pokhrel R H,Thapa B,Kafle R,et al. Co-existence of Beta-lactamases in Clinical Isolates of Escherchia coli from Kathmandu,Nepal[J]. BMC Research Notes,2014, (7):694.
[3] Kang C,Yu M W,Lee M W,et al. Epidmiology and Risk Factors of Community Onset Infections Caused by Extended-Spectrum β-Lactamase-producing Escherchia coli strains[J]. Clinical Microbiology,2012,50(2):312-317.
[4] 史宝玉,谭晓武,姜艳,等. 产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的耐药性调查分析[J]. 中国实验诊断学,2015,19(5):765-769.
[5] 黄素玲. 产超广谱β内酰胺酶大肠埃希菌的分布特点及耐药性分析[J]. 中国感染与化疗杂志,2017,17(2):182-186.
[6] 产超广谱β-内酰胺酶细菌感染防治专家委员会. 产超广谱β-内酰胺酶细菌感染防治专家共识[J]. 中华实验和临床感染病杂志,2010,4(2):207-214.
[7] 熊利华,潘翔军,张芳,等. 泌尿系统感染常见病原菌分布及耐药趋势分析[J]. 检验医学,2013,28(4):348-350.
[8] 张波,府伟灵,张晓兵,等. 尿路感染患者的病原菌分布及其耐药性[J]. 中华医院感染学杂志,2006,16(11):1291-1293.
[9] 李惠,宋珍,倪语星,等. 哌拉西林-他唑巴坦治疗产ESBLs细菌感染134例[J]. 中国感染与化疗杂志, 2010,10(2):90-93.
[10] 张雅薇,王辉. 2014年CLSI M100-S24主要更新内容解读[J]. 中华检验医学杂志,2014,37(4):256-260.
[11] 黄云昆,朱雯梅,姚瑶,等. 昆明市延安医院2001-2012大肠埃希菌耐药性变迁[J]. 中国感染与化疗杂志,2015,15(2):146-148.
[12] 孙永丽,周春兰,高霞,等. 产超广谱β-内酰胺酶大肠埃希菌引起复杂性尿路感染的治疗[J]. 中国民康医学,2008,20(18):2178-2178.
[13] 胡伶俐. 硫酸依替米星抗感染的临床药理探讨[J]. 中国医药指南,2013,11(7):171-172.
[14] 陈震,孙丽,吕雄文,等. 某三甲医院抗菌药物使用情况与大肠埃希菌耐药相关性分析[J]. 安徽医药, 2015,19(4):785-788.
[15] 万永艳. 医院第3代头孢菌素类抗菌药物用量与肠杆菌科细菌耐药率相关性研究[J]. 中国药业,2016,25(23):43-45.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
安徽省自然科学基金（编号09020103002）
{{custom_fund}}
PDF(1287 KB)
